Contract Pharma Manufacturing News
-
Ardena's Nanomedicines Facility Marks €20M Expansion With First GMP Approval
4/18/2024
Oss, The Netherlands: Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
-
Ardena’s Nanomedicines Facility Marks €20M Expansion With First GMP Approval
4/18/2024
Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
-
TriLink BioTechnologies Announces New San Diego Facility For Late Phase mRNA Drug Substance Production
4/18/2024
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility.
-
Ferring Pharmaceuticals And SK Pharmteco Enter Into Commercial Gene Therapy Manufacturing Deal
4/18/2024
Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical gene therapy Adstiladrin (nadofaragene firadenovec-vncg) for ensuring long-term future supply.
-
ExoXpert Announces Agreement with Neucore Bio to Evaluate Advanced Exosome Loading
4/17/2024
ExoXpert, a Contract Development and Manufacturing Organization (CDMO) specializing in exosome production and a subsidiary of Exo Biologics, today announces a strategic partnership with Neucore Bio, a next-generation, non-viral engineered delivery technology company to leverage ExoXpert’s platform for evaluation of advanced exosome loading.
-
Imugene And Kincell Bio Announce Strategic Manufacturing And Process Development Partnership
4/16/2024
Imugene, Ltd. (“Imugene”)(ASX: IMU) and Kincell Bio, LLC (“Kincell”), announce a strategic manufacturing and process development partnership, which includes the sale of Imugene’s North Carolina Current Good Manufacturing Practice (CGMP) manufacturing facility and the transfer of process and analytical development activities to Kincell.
-
AmplifyBio And RNAV8 Bio Announce Strategic Partnership To Support mRNA Therapeutic Developers From Sequence Design To GMP Manufacture
4/16/2024
AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services that cover target optimization, preclinical safety studies, and manufacturing scale-up, and RNAV8 Bio, an emerging startup focused on mRNA engineering platforms, are partnering to provide a one-stop shop for the development of mRNA therapeutics.
-
BioHarvest Sciences Announces New Campus For Botanical Synthesis CDMO And Expansion Of Manufacturing Capacity
4/16/2024
BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) a biotechnology company pioneering its patented Botanical Synthesis technology process, today announced the signing of two agreements: a long term lease agreement for a new 80,000 square ft. facility in Yavne, Israel, and an equipment purchase agreement for 12 state of the art GMP clean rooms.
-
Medincell Enters Into Strategic Co-Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies
4/16/2024
Medincell today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.
-
Evergreen Theragnostics Completes $26M Capital Raise To Advance Novel Radiopharmaceutical Pipeline Into The Clinic, Prepare For First Commercial Product Launch, And Expand Industry-Leading CDMO Services
4/16/2024
Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.